2009 Compounding Vaccines 
Drug Topics
JULY 11, 2025
In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations.
Pharmacy Times
JUNE 19, 2025
With this action, nitisinone is the first and only FDA-approved treatment for AKU. 1 AKU, also known as black urine disease, is a rare inherited disorder that prevents the patient’s body from completely breaking down 2 amino acids, tyrosine and phenylalanine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JUNE 25, 2025
In a new CDC report, investigators found that there was no connection between thimerosal in vaccines and autism or other neurodevelopmental conditions. Thimerosal is a mercury-containing compound that has been widely used as a preservative in some biological and drug products since the 1930s.
PharmTech
JUNE 24, 2025
cancer and vaccines), and non-immunogenic applications (e.g., cancer and vaccines), and non-immunogenic applications (e.g., Several types of mRNA-based vaccines have emerged, namely non-replicating linear mRNAs (NRM), self-amplifying mRNAs (saRNAs), and circular mRNAs (circRNAs). Types of messenger RNA (mRNA)-based vaccines.
Drug Topics
JUNE 18, 2025
Following a switch in Sweden’s National Immunization Program (NIP), children in the country reported an increase in pneumococcal hemolytic uremic syndrome (pHUS) from 2009 through 2024. The need for further understanding of pediatric pHUS came when cases quadrupled from 2009 to 2023 among Swedish children under 5. pneumoniae.
Pharmaceutical Technology
JUNE 30, 2025
How will RFK Jr’s American dream for vaccines play out? The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. Find out more Ground preparation work for the new site commenced in April after obtaining the building permit.
pharmaphorum
JULY 29, 2025
In the US, the pressure on Wegovy has been attributed to "the persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition" that has not been offset by a recent telehealth blitz for the drug. Website and content copyright © 2009- 2025 , pharmaphorum media limited or its licensors; all rights reserved.
Expert insights. Personalized for you.
Let's personalize your content